BACKGROUND: Artificial intelligence (AI) is transforming inflammatory bowel disease (IBD) care, but concerns over data quality, privacy, and provider familiarity remain. AIMS: To examine international health care providers' (HCPs) perceptions, clinical use of, and barriers to applying AI in IBD care. METHODS: An anonymous 17-item survey was developed and pretested by an international team. The survey was fielded internationally from January to May 2025 via social media, international IBD newsletters and email listservs. RESULTS: Of 323 IBD professionals from North America (35.3%), Europe (26.0%), Asia-Pacific (19.2%), 207 (64.1%) viewed AI as very or extremely promising. AI-assisted endoscopy was reportedly adopted by 131 (40.6%) of respondents, but only 69 (21.4%) reported applying AI in IBD care or research. Males supported AI in IBD endoscopic scoring (89.9% vs. 79.1%, p = 0.009) and radiomics more than females (86.6% vs. 75.2%, p = 0.022), while females endorsed AI for patient education more than males (81.5% vs. 70.6%, p = 0.026). 145 (44.9%) respondents were concerned about AI usage in IBD care. Females were less concerned about cost (18.5% vs. 30.1%, p = 0.019) and more concerned about oversight (28.7% vs. 14.7%, p = 0.003). Concerns regarding AI usage decreased with age (OR 0.021 for age > 55 compared to age 25-34 years old; 95% CI 0.13-0.84). Exposure to IBD-focused AI-based tools was associated with more favorable perceptions of AI use in IBD care (OR 2.63, 95% CI 1.25-5.53). CONCLUSION: Based upon survey results, HCPs had concerns over insufficient education, regulatory ambiguity, and perplexing implementation strategies for AI. Proven clinical benefit (74.9%) and adequate AI training (72.1%) are the top solutions for enabling the appropriate adoption of AI tools in IBD.
Devi et al. (Sun,) studied this question.